Bladder Cancer Treatment Market Size & Forecast 2035
The global bladder cancer treatment market was valued at US$5.39 billion in 2025 and is projected to reach US$9.11 billion by 2035, growing at a CAGR of 5.4% during 2026-2035. The market is expanding as immunotherapy, antibody-drug conjugates, intravesical therapies, gene-based treatments, and biomarker-directed approaches gain a larger role across non-muscle-invasive, muscle-invasive, and metastatic bladder cancer.
Treatment pathways changed rapidly during 2025 and 2026. Pembrolizumab plus enfortumab vedotin has moved into perioperative muscle-invasive bladder cancer, durvalumab has expanded across both muscle-invasive and high-risk non-muscle-invasive disease, and ctDNA-based molecular residual disease testing has entered FDA-approved treatment selection after cystectomy. These developments are shifting the market from treatment based mainly on stage and chemotherapy eligibility toward treatment based on disease setting, recurrence risk, molecular characteristics, and measurable residual disease.
Bladder Cancer Treatment Market Highlights
- 2025 Market Size: US$5.39 Billion
- 2035 Market Size: US$9.11 Billion
- CAGR, 2026-2035: 5.4%
- Largest Region: North America, with 42.3% market share
- Fastest-Growing Region: Asia-Pacific
- Largest Cancer Segment: Non-Muscle-Invasive Bladder Cancer
- Leading Treatment Segment: Chemotherapy, with a 36.4% share in the existing treatment analysis, while immunotherapy and ADC-based combinations are gaining share
- Key Growth Areas: perioperative ADC-immunotherapy, BCG-checkpoint inhibitor combinations, ctDNA MRD-guided therapy, intravesical drug delivery, gene therapy, IL-15 immunotherapy, and FGFR3-targeted treatment
Bladder Cancer Treatment Market Overview
Bladder cancer treatment now covers several distinct clinical markets rather than one uniform therapy pathway. Low- and intermediate-risk NMIBC relies heavily on transurethral tumor removal and intravesical treatment. High-risk NMIBC increasingly includes BCG-based immunotherapy, checkpoint inhibitors, gene therapy and bladder-preserving alternatives for patients with recurrent disease. MIBC combines systemic treatment with radical cystectomy or chemoradiation, while locally advanced and metastatic urothelial cancer has become a major market for checkpoint inhibitors, antibody-drug conjugates and biomarker-selected targeted therapy.
Global disease burden remains substantial. IARC recorded 614,298 new bladder cancer cases and 220,596 deaths in 2022, making bladder cancer the ninth most commonly diagnosed cancer worldwide. Men represented close to three-quarters of the global burden.
The large early-stage patient population is commercially important because bladder cancer frequently requires repeated cystoscopy, TURBT, intravesical therapy, and long-term surveillance. The treatment market therefore captures not only initial therapy but also recurrent disease, maintenance treatment and subsequent bladder-preservation strategies.
White-Space Opportunities in the Bladder Cancer Treatment Market
Bladder-Preserving Treatment for NMIBC
NMIBC represents 70%-80% of newly diagnosed bladder cancer cases, giving bladder-preserving treatment the largest potential patient base within the disease. Standard management includes TURBT followed by intravesical chemotherapy or BCG according to recurrence and progression risk.
The commercial opportunity is expanding as patients who recur after BCG gain access to new intravesical and immune-based options. ANKTIVA plus BCG, ADSTILADRIN, and newer intravesical mitomycin formulations have created alternatives for selected patients who previously had fewer options other than cystectomy.
Immunotherapy Moves Earlier in High-Risk NMIBC
In May 2026, FDA approved durvalumab plus BCG for BCG-naïve high-risk NMIBC. The POTOMAC trial enrolled 1,018 patients and showed a disease-free survival hazard ratio of 0.68 for durvalumab plus BCG compared with BCG alone.
This approval expands the addressable immunotherapy population beyond metastatic and muscle-invasive disease and increases the commercial importance of earlier-stage bladder cancer.
ADC-Immunotherapy Expands Across MIBC
In July 2026, FDA approved pembrolizumab plus enfortumab vedotin before and after cystectomy for adults with MIBC, extending the combination across cisplatin eligibility groups. In KEYNOTE-B15, the regimen reduced the risk of event-free survival events by 47% versus neoadjuvant gemcitabine-cisplatin followed by surgery. Pathologic complete response reached 55.8%, compared with 32.5% for the chemotherapy arm.
This creates a larger perioperative market for ADC-checkpoint inhibitor combinations and increases competition with conventional platinum-based chemotherapy.
ctDNA MRD Creates a New Diagnostic-Treatment Market
In May 2026, the FDA approved atezolizumab as adjuvant therapy for patients with MIBC who have circulating tumor DNA molecular residual disease after cystectomy, together with an authorized companion diagnostic. In IMvigor011, median disease-free survival was 9.9 months with atezolizumab versus 4.8 months with placebo, while median overall survival was 32.8 months versus 21.1 months.
This creates a new commercial pathway connecting serial liquid-biopsy testing, recurrence-risk assessment and adjuvant immunotherapy.
Intravesical Drug Delivery Is Reducing Dependence on Repeat Surgery
FDA approved ZUSDURI in June 2025 for recurrent low-grade intermediate-risk NMIBC. In the ENVISION study, 78% of evaluable patients achieved a complete response at three months, and 79% of responding patients remained in response for at least 12 months.
Repeated low-grade recurrence creates a sizeable market for nonsurgical local treatment that can reduce reliance on repeated TURBT procedures.
Bladder Cancer Treatment Market Strategic Takeaways
- The market will increase from US$5.39 billion in 2025 to US$9.11 billion by 2035, supported by a 5.4% CAGR during 2026-2035.
- NMIBC is the largest disease segment, representing 70%-80% of newly diagnosed bladder cancers and creating sustained demand for TURBT, BCG, intravesical chemotherapy, surveillance and bladder-preserving therapies.
- North America remains the largest commercial region, accounting for 42.3% of the market in the existing regional analysis and benefiting from rapid FDA adoption of new immunotherapies, ADCs, gene therapies and diagnostic-guided treatments.
- Chemotherapy held 36.4% of treatment revenue in the existing analysis, but its share faces increasing pressure as immunotherapy and ADC combinations move into perioperative and first-line treatment.
- ADC plus checkpoint inhibition is becoming one of the most important growth platforms in MIBC, strengthened by the 2026 expansion of pembrolizumab plus enfortumab vedotin across cisplatin eligibility groups.
- ctDNA MRD testing has created a new precision-oncology segment in post-cystectomy MIBC by linking molecular recurrence detection with adjuvant treatment selection.
- BCG supply remains a commercial and treatment-access constraint, sustaining demand for alternative intravesical therapies and new immunotherapy combinations. FDA continued to address the BCG shortage in its May 2026 NMIBC workshop, while Merck has invested more than US$650 million in manufacturing expansion intended to triple TICE BCG capacity.
Bladder Cancer Treatment Market Industry Trends and Strategic Insights
ADCs Are Moving from Metastatic Disease into Curative-Intent Treatment
Enfortumab vedotin established the commercial relevance of antibody-drug conjugates in advanced urothelial cancer. Its combination with pembrolizumab has now expanded into treatment before and after surgery for MIBC. The July 2026 FDA label covers perioperative use in adult MIBC patients, creating an ADC market across an earlier disease setting.
The shift is important because perioperative treatment involves defined neoadjuvant and adjuvant cycles and reaches patients before metastatic progression.
Immunotherapy Is Expanding Across the Disease Continuum
Checkpoint inhibitors now participate in high-risk NMIBC, perioperative MIBC, MRD-positive post-cystectomy disease and advanced urothelial cancer. Durvalumab, pembrolizumab, nivolumab, atezolizumab and avelumab occupy different points in the treatment pathway.
The commercial focus is moving from whether immunotherapy should be used to when it should enter the treatment sequence and which biomarker or risk group best identifies eligible patients.
Molecular Residual Disease Is Becoming Actionable
The FDA approval of atezolizumab for ctDNA-positive MIBC establishes molecular residual disease as a treatment-selection tool rather than a research-only endpoint. Serial testing can identify patients with molecular evidence of residual cancer before radiographic recurrence, creating a new role for liquid-biopsy diagnostics in bladder cancer management.
FGFR3 Testing Supports Targeted Treatment
Erdafitinib remains an important biomarker-directed therapy for locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations after prior systemic treatment. Its FDA indication requires selection using an approved companion diagnostic.
Molecular profiling therefore has direct therapeutic value in advanced urothelial cancer and supports continued growth in genomic testing.
Local Therapy Innovation Is Expanding in NMIBC
Intravesical treatment remains one of the defining features of the bladder cancer market. ZUSDURI added a nonsurgical option for recurrent low-grade intermediate-risk NMIBC, while ANKTIVA plus BCG and ADSTILADRIN address selected high-risk BCG-unresponsive disease.
BCG Supply Is Influencing Product Development
BCG remains central to high-risk NMIBC, but supply constraints have persisted. Merck states that demand has exceeded existing maximum manufacturing capacity and is developing a new facility intended to triple capacity after full operation.
The shortage has encouraged clinical use and development of alternative intravesical chemotherapy, gene therapy, cytokine-based immunotherapy, and checkpoint inhibitor combinations.
Bladder Cancer Treatment Market Scope
| Metrics | Details |
| Historical Years | 2023-2024 |
| Base Year | 2025 |
| Market Size, 2025 | US$5.39 Billion |
| Forecast Period | 2026-2035 |
| Market Size, 2035 | US$9.11 Billion |
| CAGR, 2026-2035 | 5.40% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Largest Cancer Segment | Non-Muscle-Invasive Bladder Cancer |
| Leading Treatment Segment | Chemotherapy |
| Cancer Type | NMIBC, MIBC, Metastatic Bladder Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Small Cell Carcinoma, Others |
| Grade | Low-Grade, High-Grade |
| Treatment Type | Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Gene Therapy, Intravesical Therapy, Others |
| End User | Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Academic and Research Institutes, Others |
| Regions | North America, Europe, Asia-Pacific, Latin America, Middle East and Africa |
| Revenue Unit | US$ Billion |
The segmentation follows the established bladder cancer treatment market structure while incorporating newer therapeutic categories that became more commercially relevant during 2025 and 2026.
Bladder Cancer Treatment Market Disruption Analysis
Perioperative Treatment Is Becoming More Competitive
For decades, cisplatin-based neoadjuvant chemotherapy followed by cystectomy remained the principal systemic pathway for eligible MIBC patients. Durvalumab plus gemcitabine-cisplatin entered this setting in March 2025, followed by expanded perioperative pembrolizumab-enfortumab vedotin use.
The MIBC market is therefore moving toward multiple perioperative treatment pathways competing on event-free survival, overall survival, pathologic response, toxicity and cisplatin eligibility.
Treatment Decisions Are Moving Beyond Conventional Imaging
ctDNA MRD testing changes post-cystectomy management by identifying molecular recurrence risk before conventional clinical relapse becomes evident. The 2026 atezolizumab approval directly connected a companion diagnostic with treatment eligibility.
This development creates a commercial interface between oncology therapeutics and longitudinal molecular diagnostics.
Early-Stage Bladder Cancer Is Becoming a Pharmaceutical Growth Market
NMIBC historically relied heavily on TURBT and BCG. New drug approvals are expanding pharmaceutical treatment across both BCG-naïve and recurrent disease.
Durvalumab plus BCG now addresses BCG-naïve high-risk NMIBC, while ANKTIVA, ADSTILADRIN and other bladder-preserving products address treatment after BCG failure or recurrence.
Local Delivery Technologies Are Challenging Repeat TURBT
Recurrent low-grade NMIBC can require repeated endoscopic surgery. Intravesical mitomycin formulations designed to maintain drug exposure inside the bladder are creating a pharmacologic alternative for selected recurrent patients. The 78% complete response observed with ZUSDURI at three months supports this treatment direction.
Bladder Cancer Treatment Market Dynamics
Driver: High Global Incidence and Long-Term Treatment Requirements
Bladder cancer accounted for 614,298 new cases globally in 2022. Europe recorded 224,777 cases, Asia 215,755 and Northern America 95,546.
The commercial impact extends beyond new diagnoses because NMIBC frequently requires repeated cystoscopy, tumor resection, maintenance treatment and retreatment after recurrence.
Driver: Expansion of Immunotherapy into Earlier Disease
The approval of durvalumab plus BCG for BCG-naïve high-risk NMIBC and expanded perioperative checkpoint-inhibitor regimens in MIBC materially increase the number of patients eligible for immune-based treatment.
Driver: ADC Adoption in Urothelial Cancer
Enfortumab vedotin has moved from advanced urothelial cancer into perioperative MIBC. In KEYNOTE-B15, pembrolizumab plus enfortumab vedotin reduced the risk of an event-free survival event by 47% compared with neoadjuvant gemcitabine-cisplatin and surgery.
This creates demand for ADC manufacturing, combination treatment, toxicity management and multidisciplinary perioperative care.
Driver: Growing Biomarker Use
FGFR3 alterations already guide erdafitinib treatment, while ctDNA MRD now guides atezolizumab use after cystectomy. Biomarker testing is therefore becoming a routine commercial component of advanced and perioperative bladder cancer care.
Driver: New Bladder-Preserving Therapies
The treatment landscape for patients who wish to avoid or delay cystectomy has expanded through intravesical gene therapy, IL-15 agonist immunotherapy, checkpoint inhibition and newer chemotherapy-delivery systems.
Restraint: BCG Supply Constraints
BCG shortage remains a treatment-access issue in high-risk NMIBC. FDA explicitly included the current state of the BCG shortage in its May 2026 workshop on NMIBC drug development.
Supply limitations can delay treatment and increase reliance on alternative intravesical regimens.
Restraint: High Recurrence and Surveillance Burden
Even early bladder cancer requires prolonged monitoring because tumors can recur at new sites within the urothelium. NCI notes that bladder tumors commonly recur after resection, which generates repeated treatment and monitoring requirements.
For health systems, this produces a considerable lifetime cost burden involving cystoscopy, pathology, TURBT and repeat drug administration.
Restraint: Toxicity and Treatment Complexity
New combinations can improve efficacy but require management of immune-mediated adverse events, neuropathy, skin toxicity, metabolic effects and postoperative complications. Treatment selection therefore depends on performance status, renal function, comorbidities, disease stage and the ability of the hospital to manage complex systemic therapy.
Bladder Cancer Treatment Market Segment Analysis
By Cancer Type
Non-Muscle-Invasive Bladder Cancer Holds the Largest Patient Share
Non-muscle-invasive bladder cancer represents 70%-80% of newly diagnosed cases, making it the largest bladder cancer segment by patient volume. These tumors include Ta, carcinoma in situ and T1 disease and are generally managed initially with TURBT. Patients at intermediate or high risk can subsequently receive intravesical chemotherapy or BCG.
The large patient pool, combined with recurrent disease and maintenance treatment requirements, gives NMIBC substantial commercial importance. Growth is becoming stronger as pharmaceutical treatment expands beyond BCG to include durvalumab combinations, ANKTIVA, ADSTILADRIN and newer intravesical chemotherapy formulations.
Muscle-invasive bladder cancer represents the smaller but more treatment-intensive segment. MIBC generally accounts for 20%-30% of cases at diagnosis and can require neoadjuvant systemic therapy, radical cystectomy, radiation, chemotherapy and adjuvant treatment. The entry of perioperative immunotherapy and ADC combinations increases revenue per treated patient and expands pharmaceutical participation in curative-intent disease.
Metastatic bladder cancer represents a smaller patient population but remains one of the most commercially intensive segments because treatment can involve ADCs, immune checkpoint inhibitors, platinum chemotherapy and FGFR-targeted therapy.
By Histology
Urothelial or transitional cell carcinoma accounts for more than 90% of bladder cancers, making it the dominant histological segment. Squamous cell carcinoma represents 2%-7%, while adenocarcinoma accounts for close to 2%.
The dominance of urothelial carcinoma explains why most major pharmaceutical development programs and regulatory approvals are concentrated in urothelial disease.
By Treatment Type
Chemotherapy Remains the Largest Established Treatment Segment
Chemotherapy held 36.4% of the bladder cancer treatment market in 2024, making it the largest treatment category in the existing market analysis.
Chemotherapy remains important across multiple settings. Intravesical gemcitabine and mitomycin are used in NMIBC, while cisplatin-containing combinations remain relevant in MIBC and advanced urothelial cancer.
Its market position is changing, however, as immunotherapy and ADC combinations move into earlier lines of treatment. Pembrolizumab plus enfortumab vedotin can now be used perioperatively in MIBC, while durvalumab has entered both MIBC and BCG-naïve high-risk NMIBC.
Immunotherapy Is One of the Fastest-Expanding Treatment Categories
Immunotherapy now includes BCG, PD-1/PD-L1 checkpoint inhibitors, IL-15-based therapy and gene-based immune stimulation.
The May 2026 approval of durvalumab plus BCG broadened checkpoint-inhibitor use to BCG-naïve high-risk NMIBC. ANKTIVA plus BCG addresses BCG-unresponsive NMIBC, while pembrolizumab, nivolumab, atezolizumab and avelumab participate in later-stage or perioperative treatment.
Targeted Therapy Is Becoming More Biomarker-Defined
Erdafitinib is used for selected locally advanced or metastatic urothelial cancers carrying susceptible FGFR3 alterations. This segment remains smaller than chemotherapy or immunotherapy but carries high strategic value because treatment is directly connected to molecular testing.
Gene and Intravesical Therapy Are Expanding the NMIBC Market
ADSTILADRIN provides an intravesical gene-therapy option for high-grade BCG-unresponsive NMIBC, while ZUSDURI addresses recurrent low-grade intermediate-risk disease.
These treatments expand the market for bladder-preserving therapy and reduce the historical dependence on repeated surgery or radical cystectomy in selected patients.
By Grade
High-grade bladder cancer generates greater treatment intensity because of the higher risk of muscle invasion, recurrence and metastatic progression. High-grade NMIBC often requires BCG induction and maintenance or newer immune-based treatments, while persistent high-grade disease can lead to cystectomy.
Low-grade disease has a lower risk of cancer-specific mortality but can recur repeatedly, generating sustained demand for TURBT, cystoscopy and intravesical treatment.
By End User
Hospitals and comprehensive cancer centers represent the largest treatment setting because MIBC and metastatic disease require multidisciplinary care involving medical oncology, urologic surgery, pathology, radiology and radiation oncology.
Specialty urology and oncology clinics have a particularly important role in NMIBC because TURBT follow-up, cystoscopy, BCG and intravesical drug administration can be delivered in outpatient settings. New intravesical products are increasing the commercial importance of community urology practices.
Bladder Cancer Treatment Market Regional Analysis
North America
North America holds 42.3% of the global bladder cancer treatment market, making it the largest commercial region.
The region's leadership reflects high pharmaceutical spending, established reimbursement, strong urologic oncology infrastructure and early access to new FDA-approved drugs. During 2025 and 2026, the United States added several important treatment pathways, including durvalumab in perioperative MIBC, ZUSDURI in recurrent low-grade NMIBC, atezolizumab for ctDNA MRD-positive MIBC, durvalumab plus BCG in high-risk NMIBC and expanded pembrolizumab-enfortumab vedotin use in MIBC.
Northern America represented 15.6% of global bladder cancer incidence in 2022, equal to 95,546 new cases. The commercial share is therefore substantially higher than its global incidence share, reflecting higher treatment expenditure and adoption of premium oncology therapies.
Europe
Europe carries the world's largest regional bladder cancer incidence burden. The region recorded 224,777 new cases in 2022, representing 36.6% of global incidence.
High incidence rates in Southern and Northern Europe create sustained demand for TURBT, BCG, cystectomy, chemotherapy and systemic oncology treatment. A 2026 epidemiological analysis reported particularly high incidence rates in Southern Europe, with an age-standardized rate of 28.7 per 100,000, followed by Northern Europe at 20.4 per 100,000.
The region is also adopting newer perioperative regimens. In June 2026, the European Commission approved pembrolizumab plus enfortumab vedotin for cisplatin-ineligible resectable MIBC.
Asia-Pacific
Asia-Pacific is expected to record the fastest market growth through 2035 as diagnosis improves, oncology capacity expands and access to advanced therapies increases.
Asia accounted for 215,755 new bladder cancer cases in 2022, equal to 35.1% of global incidence. Although age-standardized incidence rates are lower in several Asian countries than in Europe, the region has a large absolute patient population.
China and Japan are particularly important. China recorded 92,883 new cases in 2022, while Japan recorded 34,568. Growing use of immunotherapy, targeted therapy, genomic profiling and multidisciplinary cancer treatment supports higher market value per patient across major Asia-Pacific health systems.
Latin America
Latin America and the Caribbean accounted for 35,791 bladder cancer cases in 2022, representing 5.8% of global incidence.
Brazil represents the largest commercial opportunity in the region because of its population size, private oncology sector and increasing use of specialist cancer treatment. Market growth is linked to access to cystoscopy, pathology, intravesical treatment and newer systemic therapies.
Middle East and Africa
Africa recorded 37,064 new bladder cancer cases in 2022, representing 6.0% of global incidence.
The region shows a different disease pattern from Western markets. Northern Africa has elevated incidence, and schistosomiasis remains relevant to bladder cancer epidemiology in parts of the region. The 2026 global analysis reported an age-standardized incidence rate of 16.3 per 100,000 in Northern Africa.
Growth opportunities are concentrated in tertiary hospitals, improved diagnostic access and expansion of modern systemic and intravesical treatment.
Bladder Cancer Treatment Country-Level Analysis
United States
The United States is the largest individual commercial market for bladder cancer treatment. The American Cancer Society projects 84,530 new bladder cancer cases and 17,870 deaths in 2026. Men account for 64,730 of the projected new cases and women for 19,800.
The U.S. also accounted for 80,404 cases in the 2022 global dataset, equal to 13.1% of worldwide incidence. Its commercial importance exceeds its case share because of early adoption of premium oncology therapies, molecular diagnostics and advanced surgical care.
China
China recorded 92,883 new bladder cancer cases in 2022, representing 15.1% of global incidence and the largest absolute country burden.
China's market opportunity is supported by its patient population, expanding hospital oncology infrastructure, increased checkpoint-inhibitor use and development of domestic oncology products.
Italy
Italy recorded 34,580 new cases in 2022, equal to 5.6% of global incidence. Its age-standardized incidence rate was 18.1 per 100,000, placing it among the highest-incidence major countries.
High incidence combined with mature oncology reimbursement makes Italy an important European market for NMIBC and MIBC treatments.
Japan
Japan recorded 34,568 cases in 2022, representing 5.6% of global incidence.
Its aging population, universal healthcare system and early adoption of oncology drugs make Japan one of the most important Asia-Pacific markets for bladder cancer therapeutics.
Germany
Germany recorded 29,035 new cases in 2022, representing 4.7% of global incidence.
Germany combines high disease burden with extensive urology infrastructure, clinical-trial participation and access to modern immunotherapy and targeted treatment.
United Kingdom
The United Kingdom recorded 23,643 new cases in 2022, accounting for 3.8% of global bladder cancer incidence.
Treatment demand is concentrated across NHS urology and oncology networks, with increasing relevance for bladder-preserving approaches and newer perioperative regimens.
India
India recorded 22,548 new bladder cancer cases in 2022, representing 3.7% of global incidence.
The commercial market remains smaller relative to the patient pool than in the United States or Western Europe, but expanding cancer centers, health insurance coverage and access to specialty pharmaceuticals support long-term growth.
Spain
Spain recorded 21,418 cases in 2022, equal to 3.5% of worldwide incidence, and had an age-standardized incidence rate of 19.3 per 100,000, the highest among the countries listed in the WCRF global incidence-rate ranking.
Bladder Cancer Treatment Market Epidemiology Analysis
Bladder cancer is the most common malignancy of the urinary tract and remains heavily concentrated among men. Global data for 2022 recorded 471,293 cases in men and 143,005 in women, meaning men represented 76.7% of new diagnoses.
Europe accounted for 36.6% of global cases, followed by Asia with 35.1% and Northern America with 15.6%. Europe also represented 38.9% of five-year prevalent cases, Asia 33.0% and Northern America 16.8%.
Smoking remains the predominant modifiable risk factor for bladder cancer. The 2026 global epidemiology study also identified strong regional variation linked to historic smoking prevalence, occupational exposures and schistosomiasis in Northern Africa.
Bladder Cancer Treatment Market Pipeline Analysis
The development pipeline is moving toward treatments that preserve the bladder, improve perioperative outcomes and use molecular signals to guide therapy.
Oncolytic viruses are emerging as an investigational approach in recurrent NMIBC. In July 2026, FDA cleared UroGen's IND for UGN-501, a next-generation oncolytic virus intended for intravesical administration. A Phase I study is planned to evaluate safety and feasibility in NMIBC.
ADC combinations remain a major clinical-development area following the expansion of enfortumab vedotin plus pembrolizumab. Programs are increasingly evaluating these agents earlier in the disease course and alongside surgery.
MRD-guided treatment is expected to expand following the regulatory validation of ctDNA-positive patient selection in MIBC. The model creates opportunities for studies in which treatment is escalated, initiated or withheld according to molecular recurrence status.
Next-generation intravesical therapies are targeting recurrent disease without cystectomy. Local delivery is attractive because it can expose the bladder directly to therapy while limiting systemic drug exposure.
Bladder Cancer Treatment Market Company Positioning
Merck & Co., Inc.
Merck has one of the strongest positions in bladder cancer through pembrolizumab. KEYTRUDA is used across advanced urothelial cancer, BCG-unresponsive NMIBC and perioperative MIBC.
Its combination with Astellas' enfortumab vedotin has become particularly important following the July 2026 FDA approval for MIBC before and after cystectomy.
Astellas Pharma and Pfizer
Astellas and Pfizer participate in the market through PADCEV. Its combination with pembrolizumab now spans locally advanced or metastatic urothelial cancer and perioperative MIBC.
The expansion into earlier disease increases the commercial reach of the ADC platform.
AstraZeneca
AstraZeneca has expanded IMFINZI across two major bladder cancer settings.
FDA approved durvalumab with gemcitabine-cisplatin followed by adjuvant durvalumab for MIBC in March 2025. In May 2026, durvalumab plus BCG was approved for BCG-naïve high-risk NMIBC.
Genentech/Roche
Genentech strengthened its precision-oncology position through the May 2026 approval of atezolizumab for ctDNA MRD-positive MIBC after cystectomy.
The approval is commercially important because it integrates Tecentriq with a companion diagnostic and serial molecular monitoring.
ImmunityBio
ImmunityBio competes in high-risk NMIBC through ANKTIVA plus BCG. FDA approved the combination in April 2024 for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.
Ferring Pharmaceuticals
Ferring participates through ADSTILADRIN, an intravesical gene therapy indicated for high-grade BCG-unresponsive NMIBC.
UroGen Pharma
UroGen has strengthened its bladder cancer portfolio through ZUSDURI for recurrent low-grade intermediate-risk NMIBC. The company is also developing UGN-501 as a next-generation oncolytic virus for NMIBC.
Johnson & Johnson
Johnson & Johnson participates in precision urothelial cancer treatment through BALVERSA, which targets susceptible FGFR3 alterations in locally advanced or metastatic disease.
Bristol Myers Squibb
Bristol Myers Squibb remains relevant through nivolumab-based treatment in urothelial cancer, including adjuvant and advanced disease settings described in current NCI treatment pathways.
Bladder Cancer Treatment Market Competitive Landscape
The competitive environment is increasingly divided into five areas: intravesical NMIBC treatment, checkpoint inhibition, ADC-based combinations, biomarker-selected targeted therapy and perioperative treatment.
Merck and Astellas have strengthened their position through KEYTRUDA plus PADCEV. AstraZeneca has expanded IMFINZI into both MIBC and high-risk NMIBC. Genentech has created a distinct MRD-guided adjuvant position with TECENTRIQ. ImmunityBio and Ferring compete in BCG-unresponsive NMIBC, while UroGen is focused on recurrent low-grade NMIBC and local drug-delivery innovation.
Future competitive differentiation will depend on event-free and overall survival, durability of bladder preservation, recurrence reduction, biomarker reach, toxicity, dosing convenience and the ability to reduce repeated surgery.
Bladder Cancer Treatment Market Key Developments
July 2026: FDA Expands KEYTRUDA Plus PADCEV in MIBC
On July 10, 2026, FDA approved pembrolizumab plus enfortumab vedotin as neoadjuvant treatment followed by continued treatment after cystectomy for adults with MIBC.
KEYNOTE-B15 showed a 47% reduction in the risk of event-free survival events, a 35% reduction in the risk of death and a 55.8% pathologic complete response rate, compared with 32.5% for neoadjuvant gemcitabine-cisplatin.
July 2026: FDA Clears UGN-501 IND
UroGen received FDA clearance to begin clinical development of UGN-501, an investigational next-generation oncolytic virus for NMIBC.
June 2026: European Commission Approves KEYTRUDA Plus PADCEV
The European Commission approved pembrolizumab plus enfortumab vedotin as perioperative treatment for cisplatin-ineligible adults with resectable MIBC.
May 2026: IMFINZI Plus BCG Approved for High-Risk NMIBC
FDA approved durvalumab plus BCG for BCG-naïve high-risk NMIBC on May 28, 2026. POTOMAC showed a 32% reduction in the risk of high-risk disease recurrence, progression or death.
May 2026: TECENTRIQ Approved for ctDNA MRD-Positive MIBC
FDA approved atezolizumab for adjuvant treatment after cystectomy in patients with ctDNA MRD-positive MIBC and simultaneously authorized a companion diagnostic for patient selection.
June 2025: ZUSDURI Approved for Recurrent Low-Grade NMIBC
FDA approved intravesical mitomycin solution for recurrent low-grade intermediate-risk NMIBC. The pivotal study reported a 78% complete response rate at three months.
March 2025: IMFINZI Approved for Perioperative MIBC
FDA approved durvalumab with gemcitabine and cisplatin before radical cystectomy, followed by durvalumab after surgery. NIAGARA reported an event-free survival hazard ratio of 0.68 and an overall-survival hazard ratio of 0.75.
Key Procurement Priorities and Buyer Evaluation Criteria
Healthcare systems purchasing or adding bladder cancer treatments to formularies increasingly assess the full treatment pathway rather than drug acquisition cost alone.
Clinical teams prioritize overall survival, event-free survival, recurrence control and duration of response. In NMIBC, bladder preservation and reduction in repeat TURBT procedures are particularly important. For perioperative MIBC, hospitals evaluate whether treatment delays surgery, improves pathologic response and adds clinically manageable toxicity.
Biomarker requirements also influence procurement. FGFR3-directed therapy requires molecular testing, while ctDNA MRD-guided treatment requires serial blood testing and an authorized companion diagnostic.
BCG availability remains an operational factor for urology practices. Institutions with constrained supply may require alternative intravesical options or allocation strategies.
- Treatment administration requirements are another consideration. Intravesical therapies require trained staff, catheter-based administration and appropriate pharmacy preparation, while ADCs and checkpoint inhibitors require infusion capacity and adverse-event monitoring.
